In the last trading session, 1.42 million PDS Biotechnology Corporation (NASDAQ:PDSB) shares changed hands as the company’s beta touched 1.89. With the company’s per share price at $3.82 changed hands at $0.45 or 13.35% during last session, the market valuation stood at $140.65M. PDSB’s last price was a discount, traded about -79.32% off its 52-week high of $6.85. The share price had its 52-week low at $2.53, which suggests the last value was 33.77% up since then. When we look at PDS Biotechnology Corporation’s average trading volume, we note the 10-day average is 0.32 million shares, with the 3-month average coming to 373.57K.
Analysts gave the PDS Biotechnology Corporation (PDSB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended PDSB as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. PDS Biotechnology Corporation’s EPS for the current quarter is expected to be -0.28.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PDS Biotechnology Corporation (NASDAQ:PDSB) trade information
Instantly PDSB was in green as seen at the end of in last trading. With action 21.66%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -23.14%, with the 5-day performance at 21.66% in the green. However, in the 30-day time frame, PDS Biotechnology Corporation (NASDAQ:PDSB) is 21.27% up. Looking at the short shares, we see there were 4.61 million shares sold at short interest cover period of 20.62 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 57.56% from its current market value. According to analyst projections, PDSB’s forecast low is 9 with 9 as the target high. To hit the forecast high, the stock’s price needs a -135.6% plunge from its current level, while the stock would need to soar -135.6% for it to hit the projected low.
PDS Biotechnology Corporation (PDSB) estimates and forecasts
Data shows that the PDS Biotechnology Corporation share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -4.98% over the past 6 months, a 6.47% in annual growth rate that is considerably lower than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 42.97%. The 2024 estimates are for PDS Biotechnology Corporation earnings to increase by 13.67%.
PDSB Dividends
PDS Biotechnology Corporation is expected to release its next quarterly earnings report in November.
PDS Biotechnology Corporation (NASDAQ:PDSB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.99% of PDS Biotechnology Corporation shares while 15.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 15.70%. There are 15.07% institutions holding the PDS Biotechnology Corporation stock share, with VANGUARD GROUP INC the top institutional holder. As of 2024-06-30, the company held 4.0465% of the shares, roughly 1.41 million PDSB shares worth $4.13 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 1.3987% or 0.49 million shares worth $1.43 million as of 2024-06-30.
